Three Cases of Merkel Cell Carcinoma Treated With Lutetium‐177 Oxodotreotide
The Journal of Dermatology · 2026-11 · 53 (11) · 1701-1705
DOI: 10.1111/1346-8138.70495 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, online erschienen am 07.09.2026. Verfasst von Michitoshi Kurisaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Lutetium, Radioisotopes, Radiopharmaceuticals. Die Arbeit nennt 15 Literaturangaben. Gefördert von: National Cancer Center Research and Development Fund.
Abstract (Originalsprache)
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer associated with early metastasis and poor outcomes in the advanced stages. Immune checkpoint inhibitors (ICIs), particularly avelumab, represent the first‐line therapy for metastatic MCC. However, effective treatment options after progression or intolerance remain limited. Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has emerged as a potential therapeutic option for tumors expressing somatostatin receptors (SSTRs). We present three patients with advanced MCC (aged 73, 45, and 77 years, respectively) treated with 177 Lu‐oxodotreotide after failure or intolerance of ICI therapy and cytotoxic chemotherapy. 111 In pentetreotide single photon emission computed tomography/computed tomography demonstrated SSTR uptake in all patients, supporting the rationale for PRRT. All patients ultimately experienced disease progression; however, one achieved transient disease stabilization with tumor reduction. The times from the first PRRT administration to death were 3.4, 4.2, and 1.4 months, respectively. No serious treatment‐related adverse events were observed. These findings suggest that 177 Lu‐oxodotreotide may represent a feasible and relatively safe option for patients with treatment‐refractory MCC, although its antitumor efficacy is limited. However, further prospective studies are required to elucidate its clinical role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
- Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Michitoshi Kurisaki, Eiji Nakano, Yoshiki Sakai, Harutaka Seshimo, Dai Ogata, Naoya Yamazaki, Kimiteru Ito, Kenjiro Namikawa
Förderung
- National Cancer Center Research and Development Fund
Zitieren
APA
Kurisaki, M., Nakano, E., Sakai, Y., Kase, M., Seshimo, H., Kage, Y., Ogata, D., Yamazaki, N., Ito, K., & Namikawa, K. (2026). Three Cases of Merkel Cell Carcinoma Treated With Lutetium‐177 Oxodotreotide. The Journal of Dermatology, 53(11), 1701-1705. https://doi.org/10.1111/1346-8138.70495
Vancouver
Kurisaki M, Nakano E, Sakai Y, Kase M, Seshimo H, Kage Y, et al. Three Cases of Merkel Cell Carcinoma Treated With Lutetium‐177 Oxodotreotide. The Journal of Dermatology. 2026;53(11):1701-1705. doi:10.1111/1346-8138.70495
BibTeX
@article{Kurisaki2026,
author = {Kurisaki, Michitoshi and Nakano, Eiji and Sakai, Yoshiki and Kase, Misaki and Seshimo, Harutaka and Kage, Yuta and Ogata, Dai and Yamazaki, Naoya and Ito, Kimiteru and Namikawa, Kenjiro},
title = {Three Cases of Merkel Cell Carcinoma Treated With Lutetium‐177 Oxodotreotide},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {11},
pages = {1701--1705},
doi = {10.1111/1346-8138.70495}
}
EUVIMED